Mati Therapeutics

Executive Summary

Mati Therapeutics is a clinical-stage biotechnology company developing a non-invasive sustained drug delivery platform for ocular diseases. Its lead product, the Evolute® Punctal Plug Delivery System, is designed to automatically release medication over an extended period, addressing the significant problem of patient non-adherence to daily eye drops in conditions like glaucoma. Founded in 2015 by industry veterans, Mati aims to improve treatment outcomes by eliminating the need for patient-administered drops. The company is headquartered in Austin, Texas, and has raised funding to advance its pipeline, though specific financial details are not disclosed. The platform technology has the potential to transform care for millions of glaucoma patients worldwide. With the global glaucoma drug market exceeding $6 billion, and adherence rates currently below 50%, Mati's solution could capture significant market share if clinical trials demonstrate safety and efficacy comparable or superior to existing therapies. The company is progressing through clinical development, with upcoming data readouts and regulatory interactions likely to serve as key catalysts. Strategic partnerships with larger ophthalmic firms could also accelerate commercialization and validate the technology.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Trial Results for Evolute in Glaucoma60% success
• Q4 2026Strategic Partnership or Licensing Deal with Major Ophthalmic Company50% success
• Q2 2026FDA Meeting Outcomes for Development Path Clarity70% success